8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease

An 8-plex version of an isobaric reagent for the quantitation of proteins using shotgun methods is presented. The 8-plex version of the reagent relies on amine-labeling chemistry of peptides similar to 4-plex reagents. MS/MS reporter ions at 113, 114, 115, 116, 117, 118, 119, and 121 m/z are used to quantify protein expression. This technology which was first applied to a test mixture consisting of eight proteins and resulted in accurate quantitation, has the potential to increase throughput of analysis for quantitative shotgun proteomics experiments when compared to 2- and 4-plex methods. The technology was subsequently applied to a longitudinal study of cerebrospinal fluid (CSF) proteins from subjects undergoing intravenous Ig treatment for Alzheimer's disease. Results from this study identify a number of protein expression changes that occur in CSF after 3 and 6 months of treatment compared to a baseline and compared to a drug washout period. A visualization tool was developed for this dataset and is presented. The tool can aid in the identification of key peptides and measurements. One conclusion aided by the visualization tool is that there are differences in considering peptide-based observations versus protein-based observations from quantitative shotgun proteomics studies.     

The τ Protein in Human Cerebrospinal Fluid in Alzheimer's Disease Consists of Proteolytically Derived Fragments

Abstract: Previous studies have shown that the levels of the microtubule-associated protein τ in the CSF of patients with Alzheimer's disease (AD) are elevated compared with age-matched controls. In spite of these findings, the nature of τ in CSF has not been well documented. In the present study, τ was immunoprecipitated from CSF of patients with AD or acute stroke, as well as normal elderly controls, followed by immunoblot analysis. In all cases, CSF τ consisted primarily of a band migrating at 26–28 kDa. In AD and stroke patients, several smaller τ fragments were also detected. No intact τ was detected in any of the CSF samples examined. Further immunoprecipitation studies showed that the majority of the τ fragments contained the amino terminus of the molecule. Treatment of CSF τ with alkaline phosphatase did not alter the electrophoretic properties of the fragments. These studies clearly demonstrate that CSF τ is truncated rather than intact.     

Immunocytochemical Detection of Anti-Hippocampal Antibodies in Alzheimer's Disease and Normal Cerebrospinal Fluid

Immunocytochemical staining was performed to investigate the presence of anti-hippocampal antibodies in cerebrospinal fluid (CSF) from patients with probable Alzheimer's disease (AD) (n = 19), aged normal controls (n = 9), and young normal controls (n = 10). Marked staining of neurons in the granule cell layer of the dentate gyrus and in pyramidal neurons in CA1-3 of the rat hippocampus was observed in 5 AD CSF samples (26%), 1 aged control sample (11%), and 1 young control sample (10%). These differences were not statistically significant. One of the immunoreactive AD CSF specimens also contained high concentrations of C5b-9, the membrane attack complex. The infrequent occurrence of anti-hippocampal antibodies in AD CSF, and the detection of similar immunoreactivity in control CSF specimens, suggest that these antibodies are unlikely to play a role in the neurodegenerative process in most individuals with AD. However, elevated C5b-9 concentration in an AD CSF specimen with marked immunoreactivity to hippocampal neurons suggests the possibility that anti-neuronal antibodies may contribute to complement activation in some AD patients.     

Variant TREM2 Signaling in Alzheimer's Disease

Alzheimer's disease is the most common form of dementia, accounting for as much as three-quarters of cases globally with individuals in low- and middle-income countries being worst affected. Numerous risk factors for the disease have been identified and our understanding of gene-environment interactions have shed light on several gene variants that contribute to the most common, sporadic form of Alzheimer’s disease. Triggering Receptor Expressed on Myeloid cells 2 (TREM2) is an important receptor that is crucial to the functioning of microglial cells, and variants of this protein have been found to be associated with a significantly increased risk of Alzheimer's disease. Several studies have elucidated the signaling processes involved in the normal functioning of the TREM2 receptor. However, current knowledge of the idiosyncrasies of the signaling processes triggered by stimulation of the variants of this receptor is limited.In this review, we examine the existing literature and highlight the effects that various receptor variants have on downstream signaling processes and discuss how these perturbations may affect physiologic processes in Alzheimer's disease. Despite the fact that this is a territory yet to be fully explored, the studies that currently exist report mostly quantitative effects on signaling. More mechanistic studies with the aim of providing qualitative results in terms of downstream signaling among these receptor variants are warranted. Such studies will provide better opportunities of identifying therapeutic targets that may be exploited in designing new drugs for the management of Alzheimer's disease.     

星形胶质细胞在阿尔茨海默病中的功能变化及分子机制

星形胶质细胞在脑内数量最多,分布最广,对神经元有营养支持的作用,并且能够调控神经元的活性。越来越多的证据表明星形胶质细胞激活参与阿尔茨海默病(Alzheimer's disease,AD)的发生和发展。在AD病理情况下,星形胶质细胞在多种因子如β淀粉样蛋白(beta-amyloid,Aβ)和促炎细胞因子的作用下被激活,激活的星形胶质细胞进一步释放一氧化氮(Nitric oxide,NO)和多种炎性因子增强炎症级联反应。功能失常的星形胶质细胞会促进Aβ的产生,减弱对Aβ的摄取和清除,导致Aβ聚集沉积形成老年斑。激活的星形胶质细胞释放的炎症因子还能显著增加神经元内tau蛋白的异常过度磷酸化,产生神经纤维缠结。本文对星形胶质细胞在AD中参与神经变性的功能变化和分子机制进行总结,为星形胶质细胞作为靶点预防及治疗AD提供一定的理论依据。     

甲基乙二醛在阿尔茨海默病中的作用

糖酵解毒性副产物甲基乙二醛（methylglyoxal,MG）以其高反应活性在阿尔茨海默病（Alzheimer''s disease,AD）发生发展过 程中起到了重要的作用。MG 在AD病人脑中累积并促进beta淀粉样蛋白(beta-amyloid peptide,A beta)的产生和寡聚。大量累积的MG 通 过形成晚期糖基化终末产物(advanced glycosylation end products,AGEs)加剧了神经元中tau 蛋白的过度磷酸化。研究还发现MG 和AGEs 均参与了AD 脑中活性氧（reactive oxygen species,ROS）的产生和炎症的发生发展。本文总结了MG 在AD 病理过程中 的作用,并加以综述。     

基于体素的形态测量学在阿尔茨海默病及轻度认知功能障碍研究中的应用

阿尔茨海默病(Alzheimer's disease,AD)是发生于老年和老年前期、以进行性认知功能障碍和行为异常为特征的中枢神经系统退行性疾病,是老年痴呆中最常见类型。轻度认知功能障碍(mild cognitive impairment,MCI)是介于正常衰老和痴呆之间的一种中间状态,指有轻度的记忆或认知损伤,但尚未达到痴呆程度的一种状态,日常生活和社会功能不受影响,其中很大一部分患者最终进展为AD。临床诊断AD患者多已达中晚期,为了能早期诊断AD及预测MCI的转归,有关AD的生物学标注物的研究成为近年来的科研热点。AD患者颅脑的大体病理特征为脑萎缩,其萎缩有别于正常老龄化所致的退行性改变,有其自身特点,这种特定形式的萎缩有可能成为AD早期诊断的生物学标志物。基于体素的形态测量学(voxel-based morphometry,VBM)是一种基于像素水平对脑核磁图像进行自动、全面、客观分析的技术,可以定量分析全脑结构、刻画出局部脑区结构特征,是一种较好的脑形态分析工具,广泛用于阿尔茨海默病及轻度认知功能障碍的研究中,本文综述了近年来其研究进展,期望为临床及科研提供参考。     

Activity-dependent neuroprotector homeobox protein: A candidate protein identified in serum as diagnostic biomarker for Alzheimer's disease

Alzheimer's disease (AD) is the most common cause of dementia of late life. To enhance our understanding of AD proteome, the serum proteins were analyzed using two-dimensional gel electrophoresis (2DE) combined with nano-high performance liquid chromatography electrospray ionization tandem mass spectrometry (nano-HPLC-ESI-MS/MS) followed by peptide fragmentation patterning. In this study, six protein spots with differential expression were identified. Five up-regulated proteins were identified as actin, apolipoprotein A-IV (Apo A-IV), inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4), alpha-1-antitrypsin (AAT), and antithrombin-III (AT-III); one protein, activity-dependent neuroprotector homeobox protein (ADNP) was down-regulated in AD patients. These proteins with differential expression in the serum may serve as potential indicators of AD. Our results suggested that ADNP may play an important role in slowing the progression of clinical symptoms of AD.     

Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome

Alzheimer's disease (AD) pathology and early‐onset dementia develop almost universally in Down syndrome (DS). AD is defined neuropathologically by the presence of extracellular plaques of aggregated amyloid β protein and intracellular neurofibrillary tangles (NFTs) of aggregated hyperphosphorylated tau protein. The development of radiolabeled positron emission tomography (PET) ligands for amyloid plaques and tau tangles enables the longitudinal assessment of the spatial pattern of their accumulation in relation to symptomatology. Recent work indicates that amyloid pathology develops 15–20 years before neurodegeneration and symptom onset in the sporadic and autosomal dominant forms of AD, while tau pathology correlates more closely with symptomatic stages evidenced by cognitive decline and dementia. Recent work on AD biomarkers in DS illustrates similarities between DS and sporadic AD. It may soon be possible to apply recently developed staging classifications to DS to obtain a more nuanced understanding of the development AD in DS and to provide more accurate diagnosis and prognosis in the clinic.     

生长因子颗粒蛋白前体和肿瘤坏死因子受体基因启动子区改变与阿尔茨 海默病的相关性研究

目的:探讨生长因子颗粒蛋白前体(PGRN)、肿瘤坏死因子受体(TNFR)基因启动子区改变以及全基因组DNA甲基化与阿尔茨海默病的相关性。方法:收集阿尔茨海默病患者血液样本80例以及健康对照血液样本80例,PCR扩增PGRN和TNFR基因启动子区并进行测序,观察两组间的单核苷酸多态性位点是否有差异。同时,用甲基化特异性PCR法检测启动子区DNA甲基化情况以及用ELISA法检测全基因组DNA甲基化水平。结果:在TNFR基因启动子区域发现阿尔茨海默病和对照组之间在多态性位点rs4149570和rs4149569有显著性差异(P0.001和P=0.033)。阿尔茨海默病患者全基因组甲基化水平为(0.79±0.29)%,显著低于对照组的(1.00±0.36)%(P0.001)。结论:TNFR基因多态性位点rs4149570和rs4149569的变异可能与阿尔茨海默病相关,全基因组甲基化水平降低可能与阿尔茨海默病相关。     

阿尔茨海默病患者红细胞膜蛋白表达的变化

目的:探讨早发性和迟发性阿尔茨海默病(AD)患者红细胞(RBC)膜蛋白表达的变化。方法:选取2016年1月至2018年1月经青海省人民医院确诊为AD的患者40例,根据年龄将AD患者分为迟发性AD患者(年龄≥65岁)23例和早发性AD患者(年龄65岁)17例。选取同期同医院19名年龄≥65岁的健康体检者为迟发性AD对照组,16名年龄65岁的健康体检者为早发性AD对照组。采用流式细胞术检测全血样本中葡萄糖转运蛋白1 (glucose transporter1, Glut1)、三磷酸腺苷结合盒转运蛋白A1(ATP-binding cassette transporter A1, ABCA1)、三磷酸腺苷结合盒超家族G成员2(ATP-binding cassette super-family G member 2,ABCG2)和三磷酸腺苷结合盒超家族B成员6 (ATP-binding cassette sub-family B member 6, ABCB6)等转运蛋白以及胰岛素受体(insulin receptor, INSR)、质膜钙泵(plasma membrane Ca2+ATPase, PMCA)等这些RBC膜蛋白的表达。结果:与同年龄段健康体检者对比,早发性AD患者RBC膜Glut1和INSR的表达水平显著增加(P均0.05),而ABCA1、ABCG2、PMCA和ABCB6表达无显著差异。与同年龄段健康体检者对比,迟发性AD患者RBC膜Glut1、INSR、ABCA1和ABCG2的表达显著增加(P均0.05),而PMCA和ABCB6表达无显著差异。结论:RBC膜Glut1、INSR、ABCA1和ABCG2蛋白表达的检测可能可作为AD病程诊断的新的参考标记物。     

RAGE 与阿尔茨海默病关系的研究进展

阿尔茨海默病属于神经系统退行性疾病,该类疾病给社会和家庭带来了沉重的负担,且目前尚无一疗效突破性药物,已经 成为一个严重的社会问题和经济问题。A茁是阿尔茨海默病的重要发病机制之一,通过多种途径介导神经损伤,其中与细胞表面 的结合位点结合而引发的病理损害成为当今的前沿认识。一方面,它们可以使A茁聚集,造成细胞膜的直接损伤;另一方面,它们 可以以受体的形式,参与细胞内的信号传导;另外,还可以激活细胞内吞作用,通过溶酶体途径造成细胞损伤。关于与A茁结合的 细胞表面结合位点,晚期糖基化终末产物受体备受瞩目。它是一种多功能受体,属于细胞表面免疫球蛋白家族成员, 在神经元、小 胶质细胞以及血管内皮细胞上都有表达,A茁是它的配体之一。研究已证实,它与A茁相互作用,通过激活细胞内不同的信号通路, 对阿尔茨海默病的发生发展发挥重要作用。随着对它的不断深入研究,有望在防治退行性疾病方面产生新的治疗策略与措施。     

ApoE与beta淀粉样蛋白在阿尔茨海默病中相互作用的研究进展

阿尔茨海默病( Alzheimer''s disease,AD)是一种中枢神经系统神经退行性疾病,至今尚未明确其发病机制,但基于其典型的 病理特征之一是beta淀粉样蛋白(amyloid-beta, Abeta)聚集,A茁沉积假说一直都是研究的重点。近年来,载脂蛋白E(apolipoprotein E, APOE)对Abeta代谢清除的影响备受关注。研究表明,APOE着4 等位基因是散发性AD 的危险因素,且APOE 对Abeta具有很高的亲和 力,不同亚型的APOE 对Abeta的代谢有不同的影响,这为对AD的认识、防止及治疗提供了新的研究方向。     

Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease

So far only the detection of 14-3-3 proteins in cerebrospinal fluid (CSF) is included in the diagnostic criteria for sporadic Creutzfeldt-Jakob disease (sCJD). However, this assay cannot be used for screening because of the high rate of false positive results in sCJD, and often negative results in variant CJD. To facilitate the differential diagnosis of CJD, we applied 2-D differential gel-electrophoresis (2-D DIGE) as a quantitative proteomic screening system for CSF proteins. We compared 36 patients suffering from sCJD with 30 patients suffering from other neurodegenerative diseases. Sample preparation was optimized in consideration of the fact that CSF is composed of blood- and brain-derived proteins, and an improved 2-D DIGE protocol was established. Using this method in combination with protein identification by MALDI-TOF-MS, several known surrogate markers of sCJD like 14-3-3 protein, neuron-specific enolase, and lactate dehydrogenase were readily identified. Moreover, a not yet identified protein with an approximate molecular mass of 85 kDa was found as marker for sCJD with high diagnostic specificity and sensitivity. We conclude that our proteomic approach is useful to differentiate CJD from other neurodegenerative diseases and expect that CSF-optimized 2-D DIGE will find broad application in the search for other brain derived proteins in CSF.     

Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry

1. Download : Download high-res image (46KB)
2. Download : Download full-size image

Highlights

• •Targeted mass spectrometry assay to quantify prion protein (PrP) in spinal fluid.
• •Precise measurement of PrP peptide concentration across protein domains.
• •Peptides are uniformly decreased in symptomatic prion disease patients.
• •Assay applicable to humans and preclinical species for drug development.

     

Applications and Challenges of Machine Learning Methods in Alzheimer's Disease Multi-Source Data Analysis

BackgroundRecent development in neuroimaging and genetic testing technologies have made it possible to measure pathological features associated with Alzheimer''s disease (AD) in vivo. Mining potential molecular markers of AD from high-dimensional, multi-modal neuroimaging and omics data will provide a new basis for early diagnosis and intervention in AD. In order to discover the real pathogenic mutation and even understand the pathogenic mechanism of AD, lots of machine learning methods have been designed and successfully applied to the analysis and processing of large-scale AD biomedical data.ObjectiveTo introduce and summarize the applications and challenges of machine learning methods in Alzheimer''s disease multi-source data analysis.MethodsThe literature selected in the review is obtained from Google Scholar, PubMed, and Web of Science. The keywords of literature retrieval include Alzheimer''s disease, bioinformatics, image genetics, genome-wide association research, molecular interaction network, multi-omics data integration, and so on.ConclusionThis study comprehensively introduces machine learning-based processing techniques for AD neuroimaging data and then shows the progress of computational analysis methods in omics data, such as the genome, proteome, and so on. Subsequently, machine learning methods for AD imaging analysis are also summarized. Finally, we elaborate on the current emerging technology of multi-modal neuroimaging, multi-omics data joint analysis, and present some outstanding issues and future research directions.